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Current status of open versus endovascular stent-
graft repair of abdominal aortic aneurysm
a bRobert B. Rutherford, MD, and William C. Krupski, MD, Denver, Colo; and San Francisco, CalifThe development of endovascular aortic aneurysm re-
pair (EVAR), now in its second decade, has involved at least
16 different devices, not including major modifications of
each, only four of which emerged from clinical trials and
gained approval from the Food and Drug Administration
(FDA; Fig 1). The main impetus behind EVAR has been its
potential for significantly reducing procedural mortality
and morbidity, but it was also expected to speed recovery
and reduce costs through decreased use of hospital re-
sources. At the outset, EVAR was touted as a better alter-
native to open repair (OPEN) in patients at high surgical
risk with large abdominal aortic aneurysms (AAAs) and to
“watchful waiting” (periodic ultrasound surveillance) in
patients with small AAAs. This new technology has evoked
a mixed response, with enthusiasts and detractors debating
its pros and cons. Bias and conflict of interest are apparent
on both sides. In this review we attempt to present a
balanced review of the current status of this controversial
competition between EVAR and OPEN, comparing them
in terms of certain key considerations, including mortality
and morbidity, complications, failure modes and durability,
and costs.
COMPARISON OF MORTALITY
This comparison is difficult, because although three
randomized trials of EVAR versus OPEN have been
launched (EVAR in the United Kingdom, the Dutch Ran-
domised Endovascular Aneurysm Management [DREAM]
trial in The Netherlands, and Open Versus Endograft Re-
pair at US Veterans Affairs Centers), none have been com-
pleted, and, aside from device trials, the selection of pa-
tients for OPEN or EVAR in clinical practice
understandably differs significantly. EVAR is less stressful
than OPEN, and therefore patients at higher risk are most
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doi:10.1016/j.jvs.2004.02.027often assigned to undergo it. However, EVAR has ana-
tomic limitations, and therefore patients with complex
anatomy are usually assigned to undergo OPEN.
Comparison of mortality with EVAR and OPEN in
US Phase II trials. Four endografts have been approved
by the FDA (to June 2003), largely on the basis of Phase II
data that compared EVAR with OPEN. Another two de-
vices could gain approval in the near future on the basis of
completed trials, and some of their Phase II data have been
either presented or published. The data for these six devices
(Fig 2) are summarized in the Table. Their trials provide
the most valid mortality data available, although they were
not randomized studies (having used concurrent control
subjects disqualified for EVAR because of unsuitable anat-
omy), because the collection and analysis of outcome data
was strictly overseen and core laboratories were used. Be-
cause tube grafts are now rarely used and aortomonoiliac
endograft with femorofemoral bypass is reserved for more
difficult cases and is therefore associated with higher mor-
tality, only bifurcation graft data are considered here.
In the Endovascular Technologies (EVT; now Ancure)
Phase II trial1 there were three perioperative deaths in the
OPEN group (2.7%), compared with two perioperative
deaths in the EVAR group (2.6%; PNS). In the Phase II
AneuRx trial there were no perioperative deaths in the
OPEN group. In the initial report of this trial by Zarins et
al2 there was a 3% mortality rate for EVAR in 190 Phase I
and II patients, but in the data presented to the FDA for
415 patients the mortality rate was 2% for EVAR (P 
NS).* In the recently reported Phase II pivotal trial of the
Excluder3 the perioperative mortality rate for EVAR was
1%, versus 0% for OPEN. Preliminary results of the pivotal
trials of three additional endografts have recently ap-
peared4-8 that include perioperative mortality data. The
FDA approved the Zenith device in June 2003, but a
complete analysis of its trial data has not yet been published.
An all-cause 30-day mortality advantage over OPEN con-
trol subjects has been noted for the standard risk group
(0.5%-2.5%), and aneurysm-related mortality was 0.5% ver-
sus 1.3% (P .04).8 The data for the high-risk group have
not been published, but no significant difference in overall
*White RA. AneuRx trial data presented to the FDA. Unpublished presen-
tation at the Thirteenth Annual Meeting of the European Society for
Vascular Surgery, Copenhagen, Denmark, Sep 4, 1999.1129
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subjects was claimed.5 The trial of the Lifepath device
recently reported a procedural mortality rate of 1.3% for
277 bifurcation grafts, “not significantly different” from
that for OPEN concurrent control subjects (data not quot-
ed).4 The original Talent device was modified to produce a
low-profile model (Talent LPS), then modified again (“en-
hanced”) when both stent spring and connecting bar frac-
tures were encountered. The original LPS device was im-
planted in 240 patients, and data were compared with those
for 126 patients undergoing OPEN; there were no deaths
in the OPEN group, versus one death (0.8%) in the EVAR
group (PNS).6 In a “confirmatory trial” of the enhanced
Talent LPS, 1-month data showed a 1.3% mortality rate.7
Three other endografts have completed or are undergoing
pivotal trials in the United States: Powerlink (Endologix),
Quantum (Cordis), and TriVascular (Boston Scientific).
The data for the Powerlink trial have been submitted to the
FDA for premarket approval (PMA) application, but are
not fully published, and in the other two trials either
enrollment or 1-year data are incomplete or comparative
data with OPEN control subjects have not been reported;
thus no data for these three devices are included here.
Complete Phase II trial data, with 1-year follow-up, have
not been published for four of the six devices featured here,
or for the completed Vanguard trial. Thus much of the
mortality data had to be obtained from other reports and
presentations.
Fig 1. Devices for endovascular AAA repair over time, f
solid line, use approved by the Food and Drug Admin
warning or device withdrawal). *Design modification.At this point, based on available Phase II data, a mor-
tality advantage in the EVAR trials has not been demon-
strated, although the trends for the more recent devices are
encouraging. Some likely explanations for this unexpected
lack of a mortality advantage are not likely to change:
mortality for OPEN has continued to improve; case selec-
tion or exclusion criteria for many of the early device trials
not only assured good results for EVAR but also for OPEN;
and even if a significant initial mortality advantage can be
shown for EVAR, deaths from associated comorbid condi-
tions are likely to override any early mortality advantage. In
three device trials in which EVAR mortality was initially
lower than that for OPEN, the advantage was lost or even
reversed by 1 year,1,3,8 and a recent FDA analysis of a fourth
device concluded that “the overall AAA-associated mortal-
ity from the AneuRx stent graft is likely to cross over and
exceed the AAA-associated mortality from open surgery at
some point in time.”9 Late overall mortality data in most
reports have either shown equivalence or have favored
OPEN. In a group of patients with AAAs at higher risk,
where one would expect the greatest initial mortality ad-
vantage for EVAR, any early advantage for EVAR is even
more likely to be obscured by late deaths related to comor-
bid conditions. This phenomenon has been observed in
analyzing the outcomes of patients unfit for surgery in the
European Collaborators on Stent Graft Techniques for
Abdominal Aortic Aneurysm Repair (EUROSTAR) regis-
try, with a 6% mortality rate for patients deemed unfit,
arodi’s device to the present. Dotted line, Clinical trials;
ion; lightning bolt, major pitfalls (failure modes, FDArom P
istrat
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the unfit patients dying within a year of the procedure.10,11
Non-trial data. Our survey of 30 published peer-
reviewed reports from 1990 to 2002 on OPEN from
centers of excellence with sizeable series12-41 yielded a
mean mortality rate of 3.2% (9291 patients), and demon-
strated a clear trend toward recent improvement. A similar
review of nine multi-institutional, community, or statewide
series,42-50 which included the exemplary 2% average oper-
ative mortality rate in the Aneurysm Detection and Man-
agement Veterans Affairs Cooperative Study (ADAM),42
produced a mean 30-day mortality rate with OPEN of just
under 5%. The FDA states that an operative mortality rate
of 3% to 5% is generally accepted.9 Comparison with “his-
torical controls” suggests a mortality advantage for EVAR
that was not borne out in the device trials. But in this
regard, it should also be noted that non-trial comparisons
of EVAR versus OPEN, from individual institutions and
often involving multiple devices, report mortality rates for
EVAR consistently higher than the device-specific trial data
presented and more in the range of that for historical
controls for OPEN, for example, 4.0%,51 5.4%,52 and
2.4%.53 EUROSTAR mortality data for EVAR are also
higher than US trial data.10,11,54-56
Nevertheless, mortality with EVAR appears to be im-
proving in non-trial EVAR versus OPEN comparisons. The
best example of this is from Australia. May et al57 per-
formed concurrent comparisons of EVAR versus OPEN
using life table methods. In their first report, the perioper-
ative mortality rate with OPEN versus EVAR was 5.6% for
both techniques, and in the next comparison it was 5.0%
with OPEN versus 2.7% for EVAR.58 However, the recent
Australian registry report cited a mortality advantage for
EVAR of 1.3%, versus 2.6% with OPEN.59 A recent pro-
pensity score-adjusted analysis of 454 consecutive patients
who received treatment of AAAs used a Cox proportional
hazard model to test the influence of the respective treat-
ment on postoperative 900-day survival estimates.53 This
technique essentially adjusted for age, organ dysfunction,
gender, and other variables that often differ significantly
between groups. The analysis revealed no clinically relevant
differences in early and midterm postoperative survival rates
between EVAR and OPEN in younger patients without
significant comorbid conditions. However, in patients with
significant preoperative risk factors, especially those with
advanced age, only EVAR “permitted” elective surgical
treatment of AAAs with acceptable mortality.
It has been suggested that overall late mortality should
not be used to compare EVAR with OPEN.60 Because the
goal is to prevent death from the AAA, it is recommended
that AAA-related death should be the primary end point.
Using this end point, and including deaths from secondary
interventions, the Stanford group claimed to show a late
mortality advantage with EVAR (AneuRx) over OPEN,
but this was not considered a valid comparison, most
significantly because it cited absolute rates for mortality to
support this claim, even though the follow-up period was
longer for OPEN than for EVAR (8 vs 5 years).61 Further-more, a recent FDA analysis of data from 1996 to 2002
showed an aneurysm-related death rate associated with the
AneuRx stent graft of 1.5% at 30 days, 1.9% at 1 year, 2.2%
at 2 years, and 2.7% at 3 years after implantation. Their
literature survey found “long-term aneurysm-associated
mortality rates associated with open surgical repair of AAA
Fig 2. Current devices with completed US clinical trials and
approval by the Food and Drug Administration granted or review
anticipated. The Ancure endograft (Guidant Cardiac and Vascular
Division, Menlo Park, Calif) is made with woven polyester non-
supported prosthetic material, with unibody construction with
hooklike attachments at the proximal and distal landing zones. The
AneuRx graft (Medtronic/AVE, Sunnyvale, Calif) is an externally
supported modular-type bifurcated device with a flexible stent ring
middle section. The EXCLUDER endograft (W. L. Gore & Asso-
ciates, Flagstaff, Ariz, and Sunnyvale, Calif) consists of a modular
bifurcated system with nitinol and nonporous expanded polytetra-
fluoroethylene (PTFE) components. Its PTFE body is fully stented
and bonded to the nitinol supporting structure with a membrane
rather than with sutures. The Zenith device (Cook, Bloomington,
Ind) is a fully supported trimodular bifurcated endograft with
barb-enhanced suprarenal stent fixation. It is the fifth iteration of
the original device introduced in Perth, Australia. The Lifepath
device (Edwards Life Sciences, Irvine, Calif) is a balloon-expand-
able, modular, bifurcated stent graft for endoluminal AAA repair
that uses a series of circumferential Elgiloy wireforms for support.
The Talent LPS stent graft (Medtronic/AVE, Santa Rosa, Calif) is
a self-expanding modular device composed of serpentine nitinol
stents inlaid in monofilament woven polyester fabric.
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mately 0.18% per year.” They concluded that “Repair of
AAA also involves late mortality risk. This risk appears to be
less for open surgery than for procedures using the AneuRx
stent graft.”9
Specific criticisms of the Stanford study should not
detract from the validity of their proposed use of AAA-
related death as a primary end point for long-term evalua-
tion; this is increasingly being accepted, and is included in
the newly published reporting standards for EVAR.62
Clearly, balanced comparisons of Kaplan-Meier or life table
estimates of long-term AAA-related death rates between
EVAR and OPEN, including secondary interventions,
from a wider, more representative practice base than a
single center of excellence (eg, post-PMA data) are needed
to help resolve the EVAR versus OPEN mortality debate.
COMPARISON OF PROCEDURAL MORBIDITY
Essentially all trials that have compared the two ap-
proaches show that, despite complication rates averaging
close to 15%, EVAR significantly reduces systemic compli-
cations compared with OPEN (primarily cardiac and pul-
monary, but not renal), but results in more local vascular
complications (eg, groin hematoma, femoral artery injury).
Improved technique and lower profile devices, and more
flexible deployment systems have decreased the vascular
complications. Renal damage related to contrast agent
overuse has been mitigated, and EVAR currently offers
significant advantages over OPEN in terms of reduced
morbidity, especially in patients at high risk with significant
cardiac and pulmonary comorbid conditions. This clear
morbidity advantage, along with decreased blood loss and
transfusion requirements, shorter hospital and intensive
care unit stays, and more rapid return to preintervention
levels of activity, is not disputed here; all are generally
conceded as the major statistically significant advantages of
EVAR over OPEN. This is well enough established that
detailed documentation here is unnecessary.
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EVAR, Endovascular aneurysm repair; NS, not significant.COMPARISON OF LATE COMPLICATIONS
AND FAILURE MODES
OPEN
Many studies have addressed the durability of OPEN,
and this advantage over EVAR is generally conceded at this
time, and not only because truly long-term EVAR data are
lacking. In a 25-year follow-up of 920 patients who under-
went OPEN,63 late graft-related complications occurred in
only 26 patients (3.2%). In a Mayo Clinic report of 1087
patients who underwent OPEN, with follow-up up to 12
years,64 pseudoaneurysm developed in 1.3% of patients,
aortoenteric fistula occurred in 0.9%, and grafts became
infected in 0.3%. A more recent report from the same
institution related a 36-year population-based experience;
21 (6.8%) of 307 patients who underwent treatment of
AAAs had graft-related problems at more than 30 days after
surgery.65 At a mean follow-up of 5.8 years, the most
common late complications were anastomotic pseudoaneu-
rysm (3.0%), graft thrombosis (2.0%), and graft-enteric
erosion or fistula (1.3%). The multicenter prospective Ca-
nadian aneurysm study66 reported only three graft-related
deaths (1.5% of all deaths) in a 6-year follow-up report of
5333 patients who survived OPEN. In a 10-year follow-up
study of 521 patients undergoing elective OPEN, German
investigators35 found only one late graft-related death
(0.2%). Separate population-based retrospective 15-year
follow-up studies from Japan and Finland have recently
been reported. The Japanese study reported no late graft-
related deaths in 392 patients who survived OPEN.67 In
the Finnish report,68 late graft-related complications were
reported in 15.4% of patients, but 5-year, 10-year, and
15-year survival rates, free from any vascular repeat inter-
ventions, were 93.8%. 88.5%, and 73.9%, respectively. Only
four late deaths (1.9%) were related to aortic graft compli-
cations. In summary, the durability of OPEN of AAAs,
established with long-term follow-up studies, is excellent,
so good that there is little or no requirement for long-term
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Although some complications noted with OPEN are
shared with EVAR (eg, graft infection; aortoenteric fistula,
aortocaval fistula, or fistulas involving the iliac vessels; false
aneurysm; graft occlusion; impotence; or buttocks claudi-
cation from hypogastric artery occlusion or thrombosis),
only graft limb thrombosis has been a significantly greater
problem with EVAR, and this primarily with aortoiliac
endografts. However, several other complications are ei-
ther specific to or much more common with EVAR. These
include endoleak, graft migration, enlargement of the an-
eurysm sac, and AAA rupture. In addition, a number of
structural failures have involved the supporting elements of
the endograft or its attachment mechanisms, most of which
are device-specific.
Endoleak. Endoleak has been the problem of primary
focus. Persistent endoleak, capable of repressurizing the
aneurysm sac, may produce AAA sac enlargement and
ultimately lead to rupture. AAA sac enlargement, and rup-
ture have been observed even in the absence of demon-
strated endoleak, creating the concept of endotension, sim-
ply defined as a state of elevated pressure within the
aneurysm sac. While it is important to determine whether
endotension represents an undetected endoleak or pressure
transmission in the absence of endoleak, through thrombus
or thin prosthesis, the feared consequences can be the same
as with endoleak.
In reviews from the EUROSTAR registry, which re-
flects the use of multiple devices, some of which have
subsequently been abandoned, the rate of freedom from
intervention to treat late complications, chiefly, endoleak,
was 89% at 1 year, 67% at 3 years, and 62% at 4 years of
follow-up.55 The Lifeline Foundation registry for US en-
dografts had collected data for 1757 patients who under-
went EVAR by early 2002.69 About 80% of patients were
followed up for at least 1 year at the time of the report, and
of these, 17% had endoleaks.
The incidence of early endoleak (at discharge or within
30 days of EVAR) is commonly in the range of 15% to
30%.55,69,70 In the Phase I and II trials of the first four
commercial devices introduced in the United States, the
initial endoleak rates were as high as 40% to 47% (all types).
The average endoleak rate at 1 year (persistent plus new) in
these first four trials was 12%, 17%, 19%, and 24%, respec-
tively. In a recent report of five different devices used at the
Cleveland Clinic,71 the observed endoleak rate (mostly
type II) at any time during the first 12 months was 30%.
Before the natural history of the various types of endoleak
was appreciated, investigators in early trials tended to delay
secondary interventions to control endoleak, but current
practice usually is to use endovascular techniques at initial
device deployment, to control all but type II endoleak.
Type II endoleaks are commonly embolized with coils or
glue in an attempt to ablate them if they persist beyond 6
months or the aneurysm sac does not shrink. Because of
increasingly aggressive secondary intervention, it not pos-
sible to determine how much improved device design andother technologic advances may have reduced the endoleak
problem. Probably both have contributed to reduction in
the frequency of endoleak, but the intrinsic endoleak prob-
lem has not been satisfactorily resolved at this time.
The importance of endoleak has engendered some
controversy. The AneuRx Clinical Trial Investigators con-
cluded that the presence or absence of endoleak on com-
puted tomography (CT) scans before hospital discharge
does not predict patient survival or aneurysm rupture rate
after EVAR.72 However, the EUROSTAR collaborators73
reviewed data for 2463 patients in the registry and found
that endoleak “predicted” conversion from EVAR to
OPEN or rupture of the AAA. Seventy percent of patients
requiring conversion and 69% of patients with rupture had
an endoleak. When the EUROSTAR data were separated
into type I endoleak (group A), types I to III endoleak
(group B), and no endoleak (group C), there was not only
a significant correlation with worse outcome for group B
(types I-III endoleak), but also a substantial trend for worse
outcomes even for group A (type II endoleak), compared
with group C (no endoleak). Parameters evaluated in-
cluded diameter enlargement greater than 8 mm (group A,
15%; group B, 18%; group C, 7%), secondary intervention
(group A, 22%; group B, 64%; group C, 6%), rupture
(group A, 0.52%; group B, 3.37%; group C, 0.25%), and
primary outcome success (group A, 72.9%; group B, 39.7%;
group C, 90.0%). At least five ruptures associated with type
II endoleaks have been reported.74 Thus it would appear
that endoleaks, even type II endoleaks, correlate with
poorer outcome, and increased costs, from more secondary
interventions aimed at controlling endoleaks and the man-
datory requirement for indefinite periodic surveillance. In
fact, a report from the University of Pennsylvania group75
showed that, although the initial hospital length of stay was
shorter with EVAR than with OPEN, this advantage was
lost during the 26-month follow-up interval, because of
frequent readmissions for treatment of procedure-related
complications, chiefly, endoleak.
Endograft limb obstruction. Obstruction of the
limb of a bifurcated endograft has occurred with almost all
devices, but has been most worrisome with those devices
without external structural support (eg, Ancure) or those
devices in which the support has been inadequate to pre-
vent kinking within tortuous iliac arteries (eg, Talent graft
with connecting bar fractures). About one third of the
former endografts required additional secondary proce-
dures to treat or avoid graft limb obstruction, but most of
these were endoluminal procedures, such as stent insertion
within the affected graft limb, and the technical success rate
was high.
Device migration. Movement of the device from its
initial location is a worrisome complication, because it
potentially can lead to late type I endoleak, AAA sac revas-
cularization, AAA enlargement, and rupture. Late migra-
tion rates were high (29%-50%) with some early proto-
types.76-78 In the recently reported experience from the
Cleveland Clinic with five different devices, there was an
overall 3.6% migration rate at 1 year; however, the migra-
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Excluder), but close to 8% with the other two devices
(AneuRx, Zenith; 8.5%).71 In another report, the AneuRx
device migrated more than 4 mm in 8% of patients, but 40%
of eccentric endografts and 19% of those with less than
1-cm neck fixation demonstrated this degree of migra-
tion.79 Cao et al80 reported that 27% of AneuRx endografts
exhibited greater than 3-mm migration at 3 years, 40% of
which required repeat intervention. The Ochsner Clinic
group81 reported that the AneuRx device showed a 7%
incidence of migration at 1 year, 20% at 2 years, and 42% at
3 years.
Rupture. AAA rupture has been the most alarming,
though least frequent, complication of EVAR. It may result
from failure to achieve or maintain AAA exclusion or occur
even with apparently successful exclusion. Migration or
dislocation at the graft ends or modular junctions may
result from inadequate grip or seal, but also from inability
of a relatively inflexible device to resist or adjust to the
distorting forces applied by changing AAA dimensions after
successful exclusion. Holes, eroded in the prosthesis by
loose, moving segments, constitute another mechanism.
The annual rate of AAA rupture after EVAR is close to 1%.
In the EUROSTAR registry data the risk for rupture shows
a steadily rising slope, with 1-year risk of 0.4%, 2-year risk of
2.6%, reaching 3.3% at 4 years.56
Using a variety of endografts, May et al57 observed a
2.3% rupture rate by 17 months. The AAA rupture rate
after AneuRx stent grafting was 1.09% in their clinical trial
data.82 A 4-year follow-up of Ancure bifurcated grafts
reported no ruptures,83 although some were observed after
this report. Seven ruptures were reported after EVAR with
the Ancure device, but most of these were tube grafts
deployed with the original EVT device before discovery of
hook fractures required modification of the attachment
device.74 However, the accompanying literature search in
this report revealed 40 additional ruptures related to other
devices, for a total of 47 ruptures. Adequate data were
available in the reports for 44 patients to determine that
ruptures were caused by type I endoleaks in 26 patients,
type II endoleaks in 2 patients, type III endoleaks in 11
patients, and no reported source in 5 patients.
The report of three ruptures occurring approximately 2
years after implantation called attention to this problem
with the AneuRx device.84 Shortly thereafter, Zarins et al85
analyzed seven AAA ruptures in patients who received the
AneuRx device. Of note, six of the seven ruptures occurred
late, and five of the seven were without known endoleaks.
In a 2001 description of the 4-year worldwide experience
with AneuRx,82 10 ruptures were reported. At that time it
was suggested that the new, more flexible design had
reduced the incidence of rupture from 3.4% (6 of 174) to
0.4% (4 of 1018), but an updated analysis to corroborate
this with the much larger numbers of subsequent ruptures
has not been published. On April 27, 2001, the FDA issued
a warning regarding the AneuRx device, citing “concern
with reports of approximately 25 AAA ruptures.” We have
been unable to find a more recent update and analysis of theAneuRx-related ruptures by the AneuRx investigators since
the analysis of 10 ruptures included in their 2001
publication.82
Structural failure. Late structural failure has been
observed with several of the endograft devices. Fractures
involving the hooks and welds of the attachment device
were discovered in the EVT/Ancure device, and long-term
follow-up showed that hook fractures developed in almost
40% of grafts. The angle and acuteness of the bend in the
hooks was modified, welds were eliminated, and the trial
resumed in November 1995. Since then only two isolated
cases of hook fracture have been reported, and the inci-
dence was determined to be 0.38% in a retrospective survey
of 571 cases, with no additional fractures and no adverse
clinical events found.
The MinTec Stentor device, although never used in the
United States, was acquired by Boston Scientific, rede-
signed, and trialed in the United States as the Vanguard II
device. Suture breaks occurred in about 40% of the original
Stentor design, leading to separation and dislocation of
supporting structural segments, and high late endoleak
rates and other late failures prompted withdrawal. The
Vanguard endograft had a similar fate, with up to 20%
incidence of suture breaks and then loosening or disloca-
tion of structural components. After a case report of rup-
ture due to “a periprosthetic leak from a tear in the polyes-
ter prosthesis occurring between 9 and 12 months after
implantation and located adjacent to suture breakage caus-
ing separation of two struts”86 called attention to this
problem, Boston Scientific issued a letter to Vanguard
customers admitting to six such cases. A greater but undoc-
umented number of patients with Vanguard endografts
were affected by this complication, with ruptured AAAs
producing at least four deaths. In addition, stent fractures
appeared in the upper rings,70 and ultimately the Vanguard
II device was withdrawn from the market.
The Lifepath device Phase II US trial was suspended in
April 2000 after Elgiloy wire form fractures were observed
in two cases. A follow-up report showed that this involved
mostly proximal wire forms, with an overall incidence of
23%, steadily increasing over time, ultimately to 47%. The
rupture rate was 7% in those with wire form fractures, but
the correlation of fractures with adverse events was not
statistically significant. The wire forms were made signifi-
cantly thicker, and the trial resumed without any wire form
fractures subsequently observed in the modified device.4
The Talent stent graft was associated with development
of stent spring fractures (n  9; 1.4%) and C-bar fractures
(n  33; 5.5%) among 416 low-profile stent grafts (LPS)
surveyed.7 The LPS device was modified by burnishing the
nitinol to strengthen it and by repositioning the longitudi-
nal connecting bars from a lateral to a medial position to
reduce stress from positioning in tortuous iliac arteries. A
“confirmatory” trial of this “enhanced” version has been
successfully completed.7
In November 2000 a UK Medical Device Alert an-
nounced that nitinol stent ring fractures had been discov-
ered in 2 of 700 (0.29%) AneuRx implants in the United
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tomers, estimated the incidence of this problem at about
0.15%, and indicated that fractures had, at that point,
caused no adverse clinical events. The correspondence
promised a retrospective imaging survey to assess the true
incidence of the problem. Data from this survey have not
been published or formally reported at scientific meetings,
but apparently no modifications have been made or
thought necessary in relation to these structural failures.
The incidence of AneuRx stent fractures in the Mt Sinai
experience was 7%, with a mean onset of 10 months.87
Barbs were used to improve suprarenal fixation of the
Zenith endograft. Fractures were subsequently noted in
these barbs, and although no adverse events were reported,
the barbs have been made more numerous (10 rather than
4) and larger. The incidence of barb fractures has been
reported at 2.5%.8 Spine fractures were discovered in the
thoracic aortic version of the Excluder stent graft, but only
one case of “wire discontinuity” was seen on follow-up CT
scans and x-ray films from the Excluder trial itself.
Thus late structural failures have been observed with
most AAA endografts, but design modifications have been
made to overcome these in many. It is important that
structural failures have been late observations, often ap-
pearing as late as 2 years; thus these corrective measures will
require long-term follow-up to establish durability. These
late failures have prompted the FDA to extend the obser-
vation period for endografts. With routine surveillance
these problems often have been missed or discovered late,
and when fully investigated most structural problems have
increased over time. Finally, their full consequence may not
become apparent until later, as, for example, the 40% hook
fracture rate and 4.8% rupture rate in the initial EVT
cohort.74
The prospects for controlling the described failure
modes in the future are good in some respects, but limited
in others, depending on the underlying causes. Failure
modes that are device-specific should be amenable to rede-
sign; those that are operator-specific should yield to im-
proved technique, experience, and judgment. However,
aneurysm-specific causes of device failure may be more
difficult to overcome. Absence of tissue ingrowth and in-
corporation, progressive neck dilatation over time (partic-
ularly with larger AAAs, and made worse by excessive
oversizing), and the distorting forces resulting from signif-
icant changes in AAA sac dimensions that may follow
successful exclusion present major challenges to this new
technology.
COMPARISON OF COSTS
A number of early studies using Markov modeling
analysis appeared to support the claim that EVAR is cost-
effective compared with OPEN, but most were based on
the initial optimistic results with EVAR and historical data
for OPEN. For example, a Cornell University study con-
cluded that EVAR was more cost-effective than OPEN (a
0.42 quality-adjusted life year [QALY] benefit for $8692
for a cost-effectiveness ratio of $20,695), but the authorsassumed a mortality and major morbidity rate of 1.1% for
EVAR and 8.8% for OPEN.88 However, they indicated that
cost-effectiveness of EVAR was critically dependent on its
producing a large reduction in the combined mortality and
long-term morbidity compared with OPEN. These caveats
proved prescient when the adverse outcomes of subsequent
device-specific trials were reported. Bosch et al89 used a
Markov decision model to evaluate QALY and lifetime
costs of EVAR versus OPEN, and concluded that EVAR
was cost-effective for a hypothetical cohort of 70-year-old
men each with an AAA with diameter of 5 to 6 cm. Zierler
and Gray90 recently published a review of the principles of
cost-effectiveness analysis using EVAR versus OPEN stud-
ies to illustrate its problems and complexities.
While it had been expected that costs should be re-
duced with EVAR, because reductions in systemic compli-
cations, length of stay in both intensive care units and the
hospital, reduced use of blood, laboratory studies, and
other resources, well documented to be true in the clinical
trials of most devices, all should lead to significant hospital
cost savings; however, in studies using actual cost data,
some of these cost savings are offset by increased costs
elsewhere. Sternbergh and Money91 reported that bed,
pharmacy, and blood bank costs were less with EVAR,
operating or procedure room costs were equivalent, but
diagnostic costs were higher, mainly because of increased
imaging costs with EVAR. However, the high cost of the
endograft device itself almost overwhelmed other cost con-
siderations, accounting for 52% of total EVAR costs. Based
on estimated costs for 131 patients undergoing EVAR and
49 patients undergoing OPEN as part of an FDA Phase II
prospective multicenter AneuRx trial, total inpatient hospi-
tal costs for EVAR were significantly higher than for OPEN
($19,985  7396 vs $12,546  5944, respectively; P 
.0001). A collaborative multistate US group reported cur-
rent hospital costs and Medicare reimbursement for endo-
vascular AAA repair in a 2003 study.92 The costs for EVAR
with Ancure and AneuRx grafts were analyzed at seven
hospitals (three university, four community). The mean
total hospital cost for EVAR was $22,999, and mean reim-
bursement, weighted by case mix, was $20,837, resulting
in a net average loss of $2162. Again, the main cost with
EVAR was for the device (57%).
Thus far, most cost comparisons between the two
approaches have focused only on hospital costs, most in-
cluding the cost of the device and its deployment, but none
have added the professional fees involved in these proce-
dures, which are usually greater with EVAR. Furthermore,
previous studies have not considered for inclusion in anal-
ysis a number of costs, some major, that are incurred before
and after hospitalization for the procedure. These include
the cost of imaging procedures performed before referral,
or after referral and before accepting the patient as having
suitable anatomy for EVAR, studies not required for
OPEN; the cost of periodic surveillance, for example, plain
x-ray films, CT scans, and duplex scans, which is mandatory
with EVAR and is performed with increased frequency in
patients with endoleaks; the costs of secondary interven-
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finally, the subtle costs of liberalizing intervention for
smaller AAAs, a prevalent though not (yet) justified prac-
tice. The effect of all of these costs is that overall costs are
increased, possibly critically in countries with fixed or lim-
ited resources for delivering health care. The total costs
with EVAR may well be closer to twice those with OPEN.
In fairness, the costs for developing, bench and clinical
testing, and successful marketing of AAA endograft devices
in this competitive field are tremendous. Most devices have
had to be taken over by large corporations to complete
clinical trials and be successfully marketed. However, two
successfully trialed devices have recently become casualties
of financial constraints. Guidant withdrew the Ancure graft
in late 2003, after a $92.4 million settlement of a federal
lawsuit (10 felonies stemming primarily from making false
statements or incompletely reporting data to the FDA),
even though “the problems have been resolved,” “none of
the 18,000 patients with the endograft are in danger,” and
the device had very low migation and rupture rates, and was
still approved, purportedly because of financial consider-
ations. Recently Edwards Life Sciences announced that,
despite the positive results of its pivotal trial and “continu-
ing to seek premarket approval,” it “must seek new strate-
gies for the AAA Lifepath” (ie, might divest itself of the
device), because it “must prioritize its investments based on
expected returns” and direct “monies toward other initia-
tives.” Medicolegal costs may also detract further from
profitability. As Barry Katzen recently remarked, the num-
ber of internet sites representing lawyers seeking patients
who have undergone AAA endograft repair may be 40 to
60, and is likely to grow.
THRESHOLD FOR INTERVENTION
One final issue in comparing the two approaches is
whether the diameter threshold should be lowered for
EVAR versus OPEN. Patients with smaller AAAs have
commonly been considered candidates for EVAR, and
many patients in the device trials have had small AAAs. For
example, most patients in a recent AneuRx report had
AAAs of a size for which the United Kingdom Small
Aneurysm Trial (UKSAT) and ADAM trials showed no
benefit.93 The risk with EVAR has been presumed to be less
than with OPEN, but small AAAs are more likely to have
favorable anatomy and better outcomes than larger AAAs
with EVAR. One study confirmed that AAAs less than 5.0
cm in diameter are more likely to be successfully repaired
with EVAR,94 and another recent report, an analysis of
EUROSTAR data, showed statistically significant correla-
tions between size (4.0-5.4 cm vs 5.5-6.4 cm vs 6.5 cm)
at 3 years and all six outcomes measured (proximal and
distal type I endoleak, overall and AAA-related deaths,
conversion to OPEN, and post-EVAR rupture).95 A com-
puter model96 showed a small benefit (0.1-0.4 QALYs)
with EVAR over OPEN and that it substantially reduced
the optimal threshold diameter for intervention at age 80
years (from 8.1 cm to 5.7 cm), but only in older patients in
poor health, and the benefit of EVAR in this populationwas small (0.2 QALYs). Furthermore, although outcomes
with EVAR are clearly better with small AAAs, they are
likely also better with OPEN, and it must be remembered
that the annual risk for rupture of small AAAs in the size
range studied in the UKSAT97 and the ADAM trial42 was
small, close to 1%. This is in agreement with the Mayo
Clinic study.98 Taken as a whole, these considerations do
not support a reduction in the threshold for intervention
with EVAR compared with OPEN. Recent guidelines of
the joint vascular societies suggest a 5.5-cm AAA diameter
threshold for either intervention in most patients.99 How-
ever, some size threshold reduction should be considered
in women, who had a threefold increase in risk for rupture
in the UKSAT100 and a fourfold higher risk for rupture in
the Kingston study,101 and also for otherwise healthy pa-
tients with significant or multiple risk factors known to
correlate with rupture, such as first-degree relative family
history, hypertension, irregular shape (eccentric, saccular),
rapid growth rate (0.5 cm/y), even though specific guid-
ance for threshold reduction for these factors has not been
generated in clinical studies.
CONCLUSIONS
There has been great progress in EVAR over the almost
decade and a half since its introduction. Initial technical
success rates have risen from less than 90% to 97% or higher,
and the need for conversion to OPEN has been greatly
reduced. The early endografts have been modified, and new
endografts have been introduced with technology designed
to correct previous problems. Adjunctive devices, such as
extenders, and rescue techniques have been developed, and
device profiles have been decreased. Deployment systems
have been improved. No doubt the technology will con-
tinue to improve, and we are reminded to be patient, with
the history of aortic valve development as an example.
However, some caution is in order. The main problems
blocking more widespread EVAR acceptance include the
appearance of late failure modes; lack of proved durability;
absence of an overall mortality benefit, even though aneu-
rysm-related death may be reduced; unresolved endoleak
problems and inadequate understanding of the nature and
seriousness of the endotension phenomenon; frequent
need for secondary procedures; small but worrisome migra-
tion and rupture rates; need for indefinite surveillance; and
higher costs.
Use of endografts to repair AAAs that are small (4.0-
5.5 cm in diameter, with low risk for rupture) or have
unfavorable anatomy (with much poorer EVAR out-
comes), and use of EVAR in patients who are fit for OPEN
and have an otherwise reasonable longevity when the du-
rability of EVAR has not been well-established seems im-
prudent, at least at this point in the evolution of this new
technology. On the other hand, EVAR is an appropriate
elective treatment in patients with AAAs who have signifi-
cant comorbid conditions and suitable anatomy, and in
patients with relatively limited life expectancy and larger or
enlarging AAAs. This individualized, selective approach to
the use of EVAR versus OPEN for AAA treatment is
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committee of the American Association for Vascular Sur-
gery and the Society for Vascular Surgery.99 This also
agrees with a recent FDA analysis of the only available
EVAR device with long-term data.9 Finally, a decision-
model analysis of data from the EUROSTAR registry also
suggests that EVAR is preferred in older patients at higher
operative risk, and OPEN is preferred in younger patients at
low operative risk.102 Further technologic improvements
may well justify an increasing role for EVAR, if and when
durability is established, because that will not only enable
its use in fit patients with suitable anatomy, but will remove
the cost and psychologic burden of mandatory surveillance.
Until such time, a little “golden rule” medicine is in order
in applying this new technology.
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